Status:
COMPLETED
Artificial Intelligence to Search for Abnormalities in Ambulatory Cancer Patients
Lead Sponsor:
Institut de Cancérologie de Lorraine
Conditions:
Solid Tumor
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
During treatment, cancer patients may experience side effects related to their disease but also to the different treatments they receive. Currently, adverse effects and toxicities are well codified i...
Eligibility Criteria
Inclusion
- Follow-up for a solid tumor
- Chemotherapy treatment (oral and/or injectable) scheduled or in progress
- Life expectancy \> 3 months
- Performance Status (PS) \< 3
- Have an internet connection or assistance to answer questions throughout the study (nurse, family members, etc.)
- Patient having understood, signed and dated the consent form
- Patient affiliated to the social security system
Exclusion
- Lack of means to answer the online questionnaires
- Patient in another therapeutic trial with an experimental molecule
- Patients and their families who cannot read or speak French
- Persons deprived of liberty or under guardianship (including curatorship)
Key Trial Info
Start Date :
August 3 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 13 2023
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05412420
Start Date
August 3 2022
End Date
October 13 2023
Last Update
November 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut de Cancerologie de Lorraine
Vandœuvre-lès-Nancy, France, 54500